The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare autoimmune disorder about 75,000 to 100,000 people in the US have this disease.
A full report of Scleroderma Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/scleroderma-therapeutics-market
This disease is more common to females between the ages of 30 and 50. As per the United Nations, the global population in 2019 was 7.7 billion, out of which, around 4 billion are females. Out of this, around 50% is the target population in the age range of 15 to 50 years. It is equivalent to around 1.9 billion of the female population. This population is expected to increase to around 2.1 billion by 2025. The rapid increase in the number of the disease-prone population is anticipated to be a key factor contributing to the growth of the scleroderma therapeutics market across the globe.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/scleroderma-therapeutics-market
Boehringer Ingelheim International GmbH, Celgene Corp., arGentis Pharmaceuticals, LLC, Kadmon Holdings, Inc., Emerald Health Pharmaceuticals, Inc., Cytori Therapeutics Inc., Corbus Pharmaceuticals Holdings, Inc., Bayer AG, F. Hoffmann La-Roche Ltd., Bristol-Myers Squibb Company, and so on are the prominent players operating in the scleroderma therapeutics market across the globe. The major players of the market are making hefty investments in the R&D of novel therapies for the improved treatment of scleroderma. The continuous efforts of the market players in the development of new therapies are driving the growth of the global market.
The recent development in Market
- In June 2020, Bristol Laboratories Ltd., a UK-based pharmaceutical company had launched Amlodipine besilate tablets in 2.5mg dose. Amlodipine belongs to the class of calcium channel blockers. The launch of this medicine is anticipated to make a contribution to the market growth of scleroderma therapeutics.
- In September 2019, Correvio Pharma Corp. pharmaceutical company focused on commercializing hospital drugs had received US FDA approval to review United Therapeutics Corporation’s New Drug Application (NDA) for Trevyent (treprostinil) for the treatment of pulmonary arterial hypertension (PAH).
Global Scleroderma Therapeutics Market Segmentation
By Drug Type
- Phosphodiesterase 5 inhibitors – PHA
- Prostacyclin Analogues
- Immunosuppressors
- Endothelin Receptor Antagonists
- Calcium Channel Blockers
- Others
By Disease Type
- Systemic Scleroderma
- Localized Scleroderma
